Inspirion Delivery Sciences LLC:
MorphaBond ER™ US commercial launch Nov 2017 (FDA-approved, first single-entity abuse deterrent ER morphine product) and RoxyBond™ (FDA approved, first and only IR abuse-deterrent opioid product) both licensed to Daiichi Sankyo, Inc. Novel extended and immediate release technologies enable pain medications with abuse deterrent features, addressing the Opioid epidemic.
US - Middle Atlantic
Biotechnology, Specialty Pharmaceutical
100 Southgate Parkway
Morristown, NJ 07960
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.